Tropical Journal of Pharmaceutical Research

Original Research Article | OPEN ACCESS

Concurrent administration of amiodarone and atenolol in the treatment of coronary artery disease complicated with arrhythmia, and its effect on serum levels of CD40L, TNF-? and IL-6

Dejin Li, Chengyue Tang, Liqiong Xu, Xin Jin, Jianli Wu, Jiuju Ran, Anfang Chen

Department of Internal Medicine-Cardiovascular, The First People's Hospital of Shuangliu District Chengdu, Chengdu 610200, Sichuan Province, China;

For correspondence:- Anfang Chen Email: fr7hu4@163.com Tel:+8218349150561

Accepted: 26 April 2022 Published: 31 May 2022

Citation: Li D, Tang C, Xu L, Jin X, Wu J, Ran J, et al. Concurrent administration of amiodarone and atenolol in the treatment of coronary artery disease complicated with arrhythmia, and its effect on serum levels of CD40L, TNF-? and IL-6. Trop J Pharm Res 2022; 21(5):1073-1078 doi: 10.4314/tjpr.v21i5.23

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the efficacy of the combination of amiodarone and atenolol in the treatment of patients with coronary artery disease (CAD) complicated with arrhythmia, and its effect on serum levels of CD-40L, TNF-α and IL-6.

Methods: One hundred and twenty CAD patients with arrhythmia on admission in The First People's Hospital of Shuangliu District Chengdu, China were assigned to groups A and B, each having 60 patients. Amiodarone was administered to all the patients, while atenolol was additionally given to patients in group A. Levels of heart function indicators, inflammatory factors, blood pressure, heart rate, adverse reaction rate (ARR) and overall efficacy were evaluated for the two groups.

Results: There were significantly improved levels of heart function indicators, and lower levels of CD40L, TNF-α and IL-6 in group A, when compared with group B (p < 0.001). Moreover, treatment effectiveness was higher in group A than in group B (p < 0.05). However, there was no significant difference (p > 0.05) in ARR between groups A and B.

Conclusion: The combined use of amiodarone and atenolol improves heart function indicators in patients with CAD and arrhythmia, reduces the levels of inflammatory factors, normalizes blood pressure and heart rate, and lowers ARR. However, further clinical trials on this combined therapy are required prior to its use in clinical practice.

Keywords: Amiodarone, Atenolol, Coronary artery disease (CAD), Arrhythmia